Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY25 results · Apr–Jun 2024
Suven Life Sciences reported revenue from operations of ₹1.01 crore (down 73.5% from Q1 FY24) and net loss of ₹28.04 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.01 | 3.80 | −73.5% | 2.39 | −57.8% |
| Other income | 4.01 | 5.64 | −28.9% | 4.28 | −6.4% |
| Total income | 5.01 | 9.44 | −46.9% | 6.67 | −24.8% |
| Profit before tax | (28.04) | (24.09) | Loss widened | (27.54) | Loss widened |
| Net profit for the period | (28.04) | (24.09) | Loss widened | (26.54) | Loss widened |
| EPS, basic (₹) | (1.29) | (1.10) | Loss widened | (1.22) | Loss widened |
| Net margin (%) | -2787.2 | -634.4 | -1112.7 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.01 | 3.80 | −73.5% | 2.39 | −57.8% |
| Other income | 3.93 | 5.64 | −30.3% | 4.28 | −8.2% |
| Total income | 4.94 | 9.44 | −47.7% | 6.67 | −26.0% |
| Profit before tax | (7.67) | (2.87) | Loss widened | (4.13) | Loss widened |
| Net profit for the period | (7.67) | (2.87) | Loss widened | (3.12) | Loss widened |
| EPS, basic (₹) | (0.35) | (0.13) | Loss widened | (0.14) | Loss widened |
| Net margin (%) | -762.0 | -75.6 | -131.0 |
Consolidated
- Filed with BSE
- 22 Aug 2024, 15:43 IST
- Board meeting
- 05 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Aug 2024, 15:43 IST
- Board meeting
- 05 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE